Arcus Biosciences Presents Promising ARC-20 Study Data

Arcus Biosciences ( (RCUS) ) just unveiled an update.

On October 6, 2025, Arcus Biosciences presented updated data from its ARC-20 Phase 1/1b study, which evaluates the efficacy and safety of casdatifan in patients with metastatic clear cell renal cell carcinoma. The data, as of August 15, 2025, showed promising results in terms of progression-free survival and disease control rates, with no unexpected safety concerns. Additionally, Arcus announced plans to expand into immunology and inflammation, with potential new drug candidates targeting conditions such as atopic dermatitis, rheumatoid arthritis, and multiple sclerosis, aiming to initiate clinical studies in 2026.

The most recent analyst rating on (RCUS) stock is a Buy with a $14.00 price target. To see the full list of analyst forecasts on Arcus Biosciences stock, see the RCUS Stock Forecast page.

Spark’s Take on RCUS Stock

According to Spark, TipRanks’ AI Analyst, RCUS is a Neutral.

Arcus Biosciences’ stock score is primarily influenced by its strong technical momentum, despite financial challenges and a weak valuation. The company’s robust revenue growth is a positive, but profitability and cash flow issues need to be addressed for long-term stability. The technical analysis suggests potential for short-term gains, but caution is advised due to overbought conditions.

To see Spark’s full report on RCUS stock, click here.

More about Arcus Biosciences

Arcus Biosciences, Inc. operates in the biotechnology industry, focusing on developing innovative cancer therapies. The company is engaged in research and development of drugs targeting various forms of cancer, with a market focus on advancing treatments through clinical trials.

Average Trading Volume: 800,619

Technical Sentiment Signal: Hold

Current Market Cap: $1.42B

For detailed information about RCUS stock, go to TipRanks’ Stock Analysis page.